QLU-C10D: a health state classification system for a multi-attribute utility measure based on the EORTC QLQ-C30
- 865 Downloads
To derive a health state classification system (HSCS) from the cancer-specific quality of life questionnaire, the EORTC QLQ-C30, as the basis for a multi-attribute utility instrument.
The conceptual model for the HSCS was based on the established domain structure of the QLQ-C30. Several criteria were considered to select a subset of dimensions and items for the HSCS. Expert opinion and patient input informed a priori selection of key dimensions. Psychometric criteria were assessed via secondary analysis of a pooled dataset comprising HRQOL and clinical data from 2616 patients from eight countries and a range of primary cancer sites, disease stages, and treatments. We used confirmatory factor analysis (CFA) to assess the conceptual model’s robustness and generalisability. We assessed item floor effects (>75 % observations at lowest score), disordered item response thresholds, coverage of the latent variable and differential item function using Rasch analysis. We calculated effect sizes for known group comparisons based on disease stage and responsiveness to change. Seventy-nine cancer patients assessed the relative importance of items within dimensions.
CFA supported the conceptual model and its generalisability across primary cancer sites. After considering all criteria, 12 items were selected representing 10 dimensions: physical functioning (mobility), role functioning, social functioning, emotional functioning, pain, fatigue, sleep, appetite, nausea, bowel problems.
The HSCS created from QLQ-C30 items is known as the EORTC Quality of Life Utility Measure-Core 10 dimensions (QLU-C10D). The next phase of the QLU-C10D’s development involves valuation studies, currently planned or being conducted across the globe.
KeywordsQuality of life Utility QLQ-C30 Multi-attribute utility instrument Cancer
The MAUCa Consortium, in addition to those named as authors, consists of the following members, all of whom made some contribution to the research reported in this paper: Stuart Peacock, Helen McTaggart-Cowan, Julie Pallant and Deborah Street. We would also like to thank the following people for their generosity in contributing data for secondary analysis: U. Abacioğlu, J. Arraras, J. Blazeby, W.-C. Chie, S. Clarke, S. Kaasa, P. Klepstad, Millennium Pharmaceuticals, K. Mystakidou, S. Peacock, R. Schwarz, N. Scott, N. Tebbutt, G. Velikova and the Australian Gastro-Intestinal Trials Group. This research was supported by a National Health and Medical Research Council (Australia) Project Grant (632662). A/Professor Janda was supported by a NHMRC career development award 1045247. Professor King was supported by the Australian Government through Cancer Australia.
This research was supported by a National Health and Medical Research Council (Australia) Project Grant (632662). Professor King was supported by the Australian Government through Cancer Australia. Dr. Norman was supported by a NHMRC early career research fellowship (1069732).
Compliance with ethical standards
Conflict of interest
The authors declare they do not have conflicts of interest.
The study was approved by the University of Sydney Human Research Ethics Committee, approval number 2012/2444. All study procedures involving human participants were in accordance with the ethical standards of institutional and national research committees and with the 1964 Helsinki Declaration and its later amendments and comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 2.Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., et al. (1993). The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365–376.CrossRefPubMedGoogle Scholar
- 3.Fayers, P. M., Aaronson, N. K., Bjordal, K., Groenvold, M., Curran, D., Bottomley, A., on behalf of the EORTC Quality of Life Group. (2001). The EORTC QLQ-C30 scoring manual (3rd ed.). Brussels: European Organisation for Research and Treatment of Cancer (EORTC).Google Scholar
- 4.Drummond, M. F., Sculpher, M. J., Torrance, G. W., O’Brien, B. J., & Stoddart, G. L. (2005). Methods for the economic evaluation of health care programmes (3rd ed.). Oxford: Oxford University Press.Google Scholar
- 5.National Institute for Health and Clinical Excellence. (2013). Guide to the methods of technology appraisal. London: NICE.Google Scholar
- 6.Mittmann, N., Evans, W. K., Rocchi, A., Longo, C. J., Au, H.-J., Husereau, D., et al. (2009). Addendum to CADTH’s guidelines for the economic evaluation of health technologies: Specific guidance for oncology products. Ottawa: Canadian Agency for Drugs and Technologies in Health. Google Scholar
- 18.Norman, R., Viney, R., Aaronson, N. K., Brazier, J. E., Cella, D. F., Costa, D. S. J., et al. (2015). Using a discrete choice experiment to value the QLU-C10D: Feasibility and sensitivity to presentation format. Quality of Life Research. doi: 10.1007/s11136-015-1115-3
- 19.Pickard, A. S., Shaw, J. W., Lin, H. W., Trask, P. C., Aaronson, N., Lee, T. A., & Cella, D. (2009). A patient-based utility measure of health for clinical trials of cancer therapy based on the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire. Value in Health, 12(6), 977–988.CrossRefPubMedGoogle Scholar
- 20.Bjordal, K., de Graef, A., Fayers, P. M., Hammerlid, E., van Pottelsberghe, C., Curran, D., et al. (2000). A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. European Journal of Cancer, 36(14), 1796–1807.CrossRefPubMedGoogle Scholar
- 21.Costa, D. S. J., Aaronson, N. K., Fayers, P. M., Grimison, P., Janda, M., Pallant, J. F., et al. (2014). Deriving a preference-based utility measure for cancer patients from the EORTC QLQ-C30: A confirmatory versus exploratory approach. Patient Related Outcome Measures, 5, 119–129.CrossRefPubMedPubMedCentralGoogle Scholar
- 22.Costa, D. S. J., Aaronson, N. K., Fayers, P. M., Pallant, J. F., Velikova, G., & King, M. T. (2015). Testing the measurement invariance of the EORTC QLQ-C30 across primary cancer sites using multi-group confirmatory factor analysis. Quality of Life Research, 24(1), 125–133.CrossRefPubMedGoogle Scholar
- 26.Costa, D. S. J., King, M. T., Aaronson, N. K., Brazier, J. E., Cella, D., Grimison, P., et al. (2014). Do cancer patients distinguish between the importance and severity of their quality of life concerns? Quality of Life Research, 23(1 Supplement), 122.Google Scholar
- 27.Arraras, J. I., Suárez, J., Arias de la Vega, F., Vera, R., Asín, G., Arrazubi, V., et al. (2011). The EORTC Quality of Life questionnaire for patients with colorectal cancer: EORTC QLQ-CR29 validation study for Spanish patients. Clinical and Translational Oncology, 13(1), 50–56.CrossRefPubMedGoogle Scholar
- 28.Arraras, J. I., Tejedor, M., Illaramendi, J. J., Vera, R., Pruja, E., Marcos, M., et al. (2001). El cuestionario de calidad de vida para cáncer de mama de la EORTC, QLQ-BR23: Estudio psicométrico con una muestra española. Psicologia Conductual, 9, 81–97.Google Scholar
- 29.Arraras Urdaniz, J. I., Villafranca Iturre, E., Arias de la Vega, F., Domínguez Domínguez, M. A., Lainez Milagro, N., Manterola Burgaleta, A., et al. (2008). The EORTC Quality of Life Questionnaire QLQ-C30 (version 3.0). Validation study for Spanish prostate cancer patients. Archivos Españoles de Urología, 61(8), 949–954.PubMedGoogle Scholar
- 32.Clarke, S. J., Yip, S., Brown, C., van Hazel, G. A., Ransom, D. T., Goldstein, D., et al. (2011). Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis. European Journal of Cancer, 47(12), 1826–1836.CrossRefPubMedGoogle Scholar
- 33.Kaasa, S., Brenne, E., Lund, J. A., Fayers, P., Falkmer, U., Holmberg, M., et al. (2006). Prospective randomised multicenter trial on single fraction radiotherapy (8Gy x1) versus multiple fractions (3Gy x10) in the treatment of painful bone metastases. Radiotherapy and Oncology, 29, 278–284.CrossRefGoogle Scholar
- 34.Mystakidou, K., Tsilika, E., Parpa, E., Kalaidopoulou, O., Smyrniotis, V., & Vlahos, L. (2001). The EORTC core quality of life questionnaire (QLQ-C30, version 3.0) in terminally ill cancer patients under palliative care: Validity and reliability in a Hellenic sample. Internation Journal of Cancer, 94(1), 135–139.CrossRefGoogle Scholar
- 38.Tebbutt, N. C., Cummins, M. M., Sourjina, T., Strickland, A. H., Van Hazel, G., Ganju, V., et al. (2010). Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: The AGITG ATTAX trial. British Journal of Cancer, 102(3), 475–481.CrossRefPubMedPubMedCentralGoogle Scholar
- 39.Tebbutt, N. C., Parry, M. M., Zannino, D., Strickland, A. H., Van Hazel, G. A., Pavlakis, N., et al. (2013). Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: The AGITG ATTAX2 trial. British Journal of Cancer, 108(4), 771–774.CrossRefPubMedPubMedCentralGoogle Scholar
- 40.Teckle, P., Peacock, S., McTaggart-Cowan, H., van der Hoek, K., Chia, S., Melosky, B., & Gelmon, K. (2011). The ability of cancer-specific and generic preference-based instruments to discriminate across clinical and self-reported measures of cancer severities. Health and Quality of Life Outcomes, 9, 106.CrossRefPubMedPubMedCentralGoogle Scholar
- 41.Velikova, G., Booth, L., Smith, A. B., Brown, P. M., Lynch, P., Brown, J., & Selby, P. J. (2004). Measuring quality of life in routine oncology practice improves communication and patient well-being: A randomized controlled trial. Journal of Clinical Oncology, 22(4), 714–724.CrossRefPubMedGoogle Scholar
- 42.Velikova, G., Sheppard, S., Campbell, L., Smith, A., Awad, N., Selby, P., et al. (2008). Randomized trial of quality-of-life measurement in oncology practice: Do oncologists need to know? ASCO annual meeting (Vol. 26, pp. 9586). Chicago: Journal of Clinical Oncology.Google Scholar
- 43.Whistance, R. N., Conroy, T., Chie, W., Costantini, A., Sezer, O., Koller, M., et al. (2009). Clinical and psychometric validation of the EORTC QLQ-CR29 questionnaire module to assess health-related quality of life in patients with colorectal cancer. European Journal of Cancer, 45(17), 3017–3026.CrossRefPubMedGoogle Scholar
- 44.Klepstad, P., Dale, O., Kaasa, S., Zahlsen, K., Aamo, T., Fayers, P., & Borchgrevink, P. C. (2003). Influences on serum concentrations of morphine, M6G and M3G during routine clinical drug monitoring: A prospective survey in 300 adult cancer patients. Acta Anaesthesiologica Scandinavica, 47, 725–731.CrossRefPubMedGoogle Scholar
- 47.Costa, D. S., Aaronson, N. K., Fayers, P. M., Grimison, P., Janda, M., Pallant, J. F., et al. (2014). Deriving a preference-based utility measure for cancer patients from the EORTC QLQ-C30: A confirmatory versus exploratory approach. Patient Related Outcome Measures, 5, 119–129. CrossRefPubMedPubMedCentralGoogle Scholar
- 48.Costa, D. S. J., King, M. T., Aaronson, N. K., Brazier, J. E., Cella, D., Grimison, P., et al. (2014). Do cancer patients distinguish between the importance and severity of their quality of life concerns? Annual Conference for the international society for quality of life research (Vol. 23, pp. 122). Berlin, Germany: Quality of Life Research.Google Scholar
- 52.Scott, N. W., Fayers, P., Aaronson, N., Bottomley, A., de Graeff, A., Groenvold, M., et al. (2008). EORTC QLQ-C30 Reference Values. Brussels: European Organisation for Research and Treatment of Cancer (EORTC).Google Scholar
- 53.Jim, H. S. L., Phillips, K. M., Chait, S., Faul, L. A., Popa, M. A., Lee, Y. H., et al. (2012). Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. Journal of Clinical Oncology, 30(29), 3578–3587.CrossRefPubMedPubMedCentralGoogle Scholar